Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer and Avillion report positive data for Bosulif against leukaemia

Pfizer and Avillion report positive data for Bosulif against leukaemia

13th December 2016

Pfizer and its development partner Avillion have announced new clinical trial data showing the effectiveness of the drug Bosulif in the treatment of chronic myeloid leukaemia.

Data from the phase III BFORE trial has shown that the drug was able to meet its primary endpoint of achieving a major molecular response at 12 months when used as a first-line treatment for patients with chronic phase Philadelphia chromosome positive chronic myeloid leukaemia.

The drug showed a superior performance compared to an established alternative for the treatment of this disease, suggesting it could be an important new therapeutic option.

Bosulif is currently indicated in the US and EU for the treatment of adult patients with Philadelphia chromosome positive chronic myeloid leukaemia with resistance or intolerance to prior therapy.

Data from this study will be used to support applications for approval of the drug in a first-line setting.

Dr Mace Rothenberg, chief development officer for oncology at Pfizer Global Product Development, said: "This is an important milestone for Pfizer's emerging haematology portfolio as we work to develop new treatments for patients with acute and chronic haematologic malignancies."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801829836-ADNFCR

We have hundreds of jobs available across the Healthcare industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.